Study of Growth Hormone and Bone in Obesity

Completed · Not applicable · Has a placebo group

Conditions studied: Obesity, Osteopenia

In brief

Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of bone loss in obesity. The development of novel imaging techniques provides an opportunity to investigate the effects of GH on skeletal structure and strength, which will provide insights into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone loss in obesity may help identify new treatment targets for this important complication. The investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal health.

Key facts

Study ID

NCT01724489

Run by

Massachusetts General Hospital

People needed

77

Starts

2013-08-01

Expected to finish

2019-04-01

Last updated by the study team

2019-12-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages 18-65 and generally healthy
• BMI ≥ 25 kg/m2
• Bone mineral density (BMD) T score ≤ -1.0 and > -2.5 (as measured by DXA)

You may not qualify if…

• For women: amenorrhea for 3 months, pregnancy or breastfeeding, polycystic ovary syndrome
• History of diabetes mellitus, cancer or other serious chronic disease
• Use of osteoporosis medications
• Anemia

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.